HopeStage
Back to all studies
CompletedNCT01654601

A Study to Compare the Pharmacokinetics Profile of DWCZP Tablet 100mg and Clozaril® Tablet 100mg

Medication studyAges 20–60South KoreaSchizophrenia
The study in practice

Understand this study

Who was this study for?

This study was for people with schizophrenia. Listed age limits: 20 years to 60 years. Other eligibility criteria applied.

Listed locations
Choongju and 4 more locationsSee all locations and recruitment
Study phase
Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.
Study clarity

Study information

Study start dateJune 2012
Recruitment status
Completed
Enrollment listed in the registry
28
Sponsor
Dong Wha Pharmaceutical Co. Ltd.
Sponsor type
Pharmaceutical company
Study type
Drug
Intervention type
Medication / drug
Study phase
Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.
Locations
South Korea
Age range
From 20 Years to 60 Years
Official registry ID
NCT01654601
Official title
Show the full official title

Clinical Trials to Compare the Pharmacokinetics Profile of DWCZP Tablet 100mg and Clozaril® Tablet 100mg After a Multi-dose Oral Administration in Schizophrenia Patients

Looking for a study you can join?

Explore recruiting studies

Get this study by email

HopeStage may email me about this study.
Loading the security check...

Recruitment & locations

Completed

Choongju · Iksan · Naju

1 more locations
  • Seoul
FAQ

Questions about this study

Who is behind this study?

The study sponsor is Dong Wha Pharmaceutical Co. Ltd., a pharmaceutical company.

Did this study involve medication?

Yes. The study involved medication, including DWCZP and Clozaril.

Who was this study for?

This study was for people with schizophrenia. Listed age limits: 20 years to 60 years. Other eligibility criteria applied.

Want to explore more studies?

Explore studies